Volume 4, Issue 4, December 2019, Page: 50-55
Distribution of Candida Species and Their Susceptibility to Antifungal Drugs in Dakar, Senegal
Khadime Sylla, Department of Parasitology-Mycology, University Cheikh Anta Diop, Dakar, Senegal; Laboratory of Parasitology-Mycology, National University Hospital of Fann, Dakar, Senegal
Roger Clement Tine, Department of Parasitology-Mycology, University Cheikh Anta Diop, Dakar, Senegal; Laboratory of Parasitology-Mycology, National University Hospital of Fann, Dakar, Senegal
Leon Amath Ndiaye, Department of Parasitology-Mycology, University Cheikh Anta Diop, Dakar, Senegal
Doudou Sow, Department of Parasitology-Mycology, University Cheikh Anta Diop, Dakar, Senegal; Laboratory of Parasitology-Mycology, National University Hospital of Fann, Dakar, Senegal
Souleye Lelo, Department of Parasitology-Mycology, University Cheikh Anta Diop, Dakar, Senegal; Laboratory of Parasitology-Mycology, National University Hospital of Fann, Dakar, Senegal
Mamadou Dia, Laboratory of Parasitology-Mycology, National University Hospital of Fann, Dakar, Senegal
Babacar Faye, Department of Parasitology-Mycology, University Cheikh Anta Diop, Dakar, Senegal
Therese Dieng, Department of Parasitology-Mycology, University Cheikh Anta Diop, Dakar, Senegal; Laboratory of Parasitology-Mycology, National University Hospital of Fann, Dakar, Senegal
Received: Oct. 4, 2019;       Accepted: Oct. 24, 2019;       Published: Oct. 30, 2019
DOI: 10.11648/j.ijidt.20190404.11      View  22      Downloads  8
Abstract
The large spectrum of Candida species and their susceptibility to antifungal drugs has made the identification of Candida species and the detection of drug resistance necessary for the management of Candida infection. This study was carried out to determine the distribution of Candida species and to evaluate their susceptibility to antifungal drugs. A prospective observational and descriptive study was conducted from March to June 2016 in the laboratory of Parasitology-Mycology at Fann University Hospital in Dakar. Samples were analyzed by direct microscopy and culture. Identification of Candida species was based on filamentation test, chlamydosporulation formation, auxanogramme (AUXACOLORTM Bio-Rad) and Candi-Select® 4 (Bio-Rad,). The susceptibility of Candida species to antifungal drugs was tested using Fungitest® (Bio-Rad) against 5-fluorocytosine, amphotericin B, miconazole, ketoconazole, itraconazole and fluconazole. A descriptive analysis was performed using Stata MP 14. Among 336 specimens received for mycological examination, 68 (20.2%) were positive for Candida. The most identified Candida species were C. albicans (58.8%), C. glabrata (16.2%), C tropicalis (7.4%), C krusei (7.4%), C. parapsilosis (4.4%), C. dubliniensis (4.4%) and C. kefyr (1.5%). The majority of isolates were susceptible to ketoconazole (94.3%), fluconazole (85.7%), amphotericin B and 5 fluoro-cytosine (88.6%). The susceptibility rates were lower for itraconazole (51.4%) and miconazole (68.6%). One strain of C. albicans was resistant to 5 fluoro-cytosine, one strain of C. glabrata and C. tropicalis were resistant to itraconazole. The results of this study provide useful information regarding the distribution of Candida species and the susceptibility to antifungal drug. Routine identification of Candida species and monitoring of resistance patterns are necessary to manage Candida infection and to control the spread of resistance in clinical isolates of Candida species.
Keywords
Candida, Identification, Antifungal Susceptibility, Fungitest, Senegal
To cite this article
Khadime Sylla, Roger Clement Tine, Leon Amath Ndiaye, Doudou Sow, Souleye Lelo, Mamadou Dia, Babacar Faye, Therese Dieng, Distribution of Candida Species and Their Susceptibility to Antifungal Drugs in Dakar, Senegal, International Journal of Infectious Diseases and Therapy. Vol. 4, No. 4, 2019, pp. 50-55. doi: 10.11648/j.ijidt.20190404.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010; 23: 253-73.
[2]
Freydière AM, Guinet R, Boiron P. Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med Mycol 2001; 39: 9-33.
[3]
Faergemann J. The role of yeasts in onychomycosis. Mycoses 1996; 39: 223-4.
[4]
Eloy O, Blanc V, Mallié M, Decousser J. W, Pina P, Allouch P. Y. Identification and antifungal susceptibility testing of two strains of Candida in 95 French hospitals. J Med Mycol, 2005; 15 (3), 117-126.
[5]
Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-478.
[6]
Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569-574.
[7]
Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
[8]
Perlroth J, CHOI B, SPELLBERG B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45; 321-346.
[9]
Hobson RP. The global epidemiology of invasive Candida infections is the tide turning? J Hosp Infect 2003; 55, 159–168.
[10]
Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155—62.
[11]
Fungitest®. Determination of the sensitivity of yeasts to antifungal agents. Bio-Rad, France, 60780.
[12]
Sylla K, Sow D, Lakhe NA, Tine RC, Dia M, Lelo S et al. Candidoses vulvovaginales au laboratoire de Parasitologie-Mycologie du Centre Hospitalier Universitaire de Fann, Dakar (Sénégal). Rev Cames Santé, 2018; 5 (2).
[13]
Seck MC, Ndiaye D, Diongue K, Ndiaye M, Badiane AS, Sow D, et al. Profil mycologique des onychomycoses à Dakar (Sénégal). J Mycol Med 2014; 24: 124-8.
[14]
Dieng Y, Sow D, Ndiaye M, Guichet E, Faye B, Tine R, et al. Identification de trois souches de Candida africana au Sénégal. J Mycol Med 2012; 22: 335-40.
[15]
Sow D, Fall B, Ndiaye M, Ba BS, Sylla K, Tine R, Lo AC, Abiola A, Wade B, Dieng T, Dieng Y. Usefulness of MALDI-TOF mass spectrometry for routine identification of Candida species in a resource-poor setting. Mycopathologia 2015; 180: 173-9.
[16]
Djohan V, Angora KE, Vanga-Bosson AH, Konaté A, Kassi FK, Yavo W, et al. In vitro susceptibility of vaginal Candida albicans to antifungal drugs in Abidjan (Ivory Coast). J Mycol Med 2012; 22: 129-33.
[17]
Kamga HY, Agem FK, Tegankam D, Toukam M, Sando Z, Somo RM. Sensibilité aux antifongiques des Candida spp isolés dans les candidoses digestives chez les sujets séropositifs au VIH à Yaoundé-Cameroun. Health Sci AND Dis 2014; 15 (3).
[18]
Bonouman-Ira V, Angora E, Djohan V, Vanga-Bosson H, Sylla-Thanon K, Beourou S, et al. Profil de résistance des Candida non albicans à Abidjan en 2011. Revue Bio-Africa 2011, 9: 27-31.
[19]
Uwingabiye J, Iken M, Zohoun AG, Boumhil L, Lemkhente Z, Naoui H, et al. Comparison of two antifungal susceptibility testing of Candida sp. isolates using agar diffusion method: Neo-sensitabs® tablets and Bio-rad® disks. J Mycol Med 2016; 26: 61-5.
[20]
Alfouzan W, Dhar R, Ashkanani H, Gupta M, Rachel C, Khan ZU. Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait. J Mycol Med 2015; 25: 23-8.
[21]
Khosravi AR, Shokri H, Mansouri P, Katiraee F, Ziglari T. Candida species isolated from nails and their in vitro susceptibility to antifungal drugs in the department of Dermatology (University of Tehran, Iran). J Mycol Med 2008; 18: 210-5.
[22]
Dieng Y. Sensibilité aux antifongiques des souches de candida responsables de candidose oropharyngée chez des sujets vivant avec le VIH. Dakar Med 2001; 2: 835.
[23]
Miranda-Cadena K, Marcos-Arias C, Mateo E, Aguirre JM, Quindós G, Eraso E. Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis. Arch Oral Biol 2018; 95: 100-7.
[24]
Sellami H, Ayadi A. Etude de la sensibilité des différentes espèces de Candida. Rev. Tun. Infectiol 2008; 2: 1-79.
[25]
Develoux M, Bretagne S. Candidoses et levuroses diverses. EMC-Maladies infectieuses 2005; 2: 119-39.
[26]
Özer TT, Durmaz S, Yula E. Antifungal susceptibilities of Candida species isolated from urine culture. J Infect and Chemother 2016; 22: 629-32.
[27]
ElFeky DS, Gohar NM, El-Seidi EA, Ezzat MM, AboElew SH. Species identification and antifungal susceptibility pattern of Candida isolates in cases of vulvovaginal candidiasis. Alexandria J Med 2016; 52: 269-77.
[28]
Paugam A. Le point sur l’antifongigramme. La Lettre de l'infectiologue 2010, 25: 222-227.
[29]
Zhang L, Zhou S, Pan A, Li J, Liu B. Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013. Int J Infect Dis 2015; 33: 1-4.
[30]
Das PP, Saikia L, Nath R, Phukan SK. Species distribution and antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals. Indian J Med Res 2016; 143: 495.
Browse journals by subject